Compare FTEK & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTEK | MREO |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.1M | 52.5M |
| IPO Year | 1997 | 2017 |
| Metric | FTEK | MREO |
|---|---|---|
| Price | $1.37 | $0.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 187.9K | ★ 4.2M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,467,000.00 | $500,000.00 |
| Revenue This Year | $14.17 | $5,184.20 |
| Revenue Next Year | $11.62 | $55.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $0.20 |
| 52 Week High | $3.64 | $2.94 |
| Indicator | FTEK | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 51.94 |
| Support Level | $1.17 | $0.22 |
| Resistance Level | $1.52 | $0.36 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 59.37 |
Fuel Tech Inc is a technology provider of boiler optimization, efficiency improvement, and air pollution reduction to utility and industrial customers. The company operates in two segments, Air Pollution Control and Fuel Chem. The Air Pollution Control technology segment includes technologies to reduce NOx emissions in flue gas from boilers, incinerators, furnaces, and other stationary combustion sources. The Fuel Chem technology segment uses chemical processes in combination with Computational Fluid Dynamics and Chemical Kinetics Modeling for boiler modeling for the control of slagging, fouling, corrosion, opacity and other sulfur trioxide-related issues in furnaces and boilers through the addition of chemicals into the furnace using TIFI Targeted In-Furnace Injection technology.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).